tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Ultragenyx completes enrollment of GTX-102 trial

Ultragenyx (RARE) announced that the Phase 3 Aspire study evaluating GTX-102 as a treatment for Angelman Syndrome is fully enrolled, with approximately 129 participants ages four to 17 with a genetically confirmed diagnosis of full maternal UBE3A gene deletion.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1